Autologous biologic treatment for equine musculoskeletal injuries: platelet-rich plasma and IL-1 receptor antagonist protein

Vet Clin North Am Equine Pract. 2011 Aug;27(2):275-98. doi: 10.1016/j.cveq.2011.05.001.

Abstract

Autologous biologic therapies such as platelet-rich plasma and autologous conditioned serum are in widespread clinical use to treat musculoskeletal pathology in horses. These substances exert a therapeutic effect through the provision of either anabolic or anti-catabolic factors, or a combination of both. This article discusses the history, experimental and clinical literature, and currently accepted preparation and usage strategies for both platelet-rich plasma and autologous conditioned serum.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Horse Diseases / etiology
  • Horse Diseases / therapy*
  • Horses / injuries*
  • Interleukin 1 Receptor Antagonist Protein / economics
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Ligaments / injuries
  • Musculoskeletal System / injuries*
  • Platelet-Rich Plasma*
  • Rupture / therapy
  • Rupture / veterinary
  • Tendon Injuries / therapy
  • Tendon Injuries / veterinary

Substances

  • Interleukin 1 Receptor Antagonist Protein